** Shares of U.S. drugmaker Eli Lilly LLY.N fall 1.5% to $856.37 premarket
** Danish rival Novo Nordisk NOVOb.CO reports late-stage data for its experimental next-generation weight-loss drug, CagriSema
** Says CagriSema helped overweight patients with type 2 diabetes (T2D) cut their weight by 15.7% after 68 weeks compared to 3.1% with placebo
** This compares to absolute weight loss of up to ~15.5% shown by LLY's obesity drug Zepbound in T2D patients at week 68 in a late-stage study - Brokerage Leerink Partners
** The CagriSema weight loss data appears a comparable cross-trial to LLY's Zepbound, brokerage says
** Up to last close, LLY stock had risen 11.5% in the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.